Introduction: Breast cancer is the most frequently diagnosed cancer among women and ranks second in terms of global incidence. Depression, anxiety, and poor quality of life (QoL) are prevalent in women with breast cancer. Supportive-expressive group therapy (SEGT) can potentially benefit these patients. Objective: This systematic review and meta-analysis evaluated the effectiveness of SEGT for women with breast cancer, by focusing on survival, QoL, anxiety, and depression as outcomes. Methods: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were adopted. The databases PubMed, Web of Science, Cochrane Library, Embase, CINHAL, and PsycInfo in English, and Sinomed, CNKI, CQVIP, and Wanfang in Chinese, were searched from inception up to May 2020 for relevant full-text articles using “SEGT,” “breast cancer,” and related terms as keywords. Randomized controlled trials (RCTs) comparing SEGT with baseline conditions of patients with breast cancer were included in the analysis. Results: Ten studies with a total of 2,879 subjects were analyzed. Overall group differences were found for survival (hazard ratio [HR] 0.82, 95% confidence interval [CI] 0.72–0.94; p = 0.004), short-term QoL (mean difference [MD] 8.02, 95% CI 4.85–11.20; p #x3c; 0.00001), long-term QoL (MD 11.30, 95% CI 6.75–15.84; p #x3c; 0.00001), Profile of Mood States score (POMS) score (MD –0.43, 95% CI –0.72 to –0.13; p = 0.005), anxiety (standardized MD [SMD] –0.30, 95% CI –0.49 to –0.10; p = 0.003), and depression (SMD –0.47, 95% CI –0.66 to –0.29; p #x3c; 0.00001). Conclusions: SEGT is effective in improving QoL and psychosocial status in breast cancer patients, but there is no convincing evidence that it has an impact on survival.
Oncol Res Treat

中文翻译：

---

支持表达性团体治疗对乳腺癌女性的有效性：系统评价和荟萃分析

简介：乳腺癌是女性中最常被诊断出的癌症，在全球发病率方面排名第二。抑郁、焦虑和生活质量差 (QoL) 在乳腺癌女性中很普遍。支持表达团体治疗 (SEGT) 可能使这些患者受益。目标：这项系统评价和荟萃分析通过关注生存、生活质量、焦虑和抑郁作为结果，评估了 SEGT 对乳腺癌女性的有效性。方法：通过了系统评价和元分析的首选报告项目指南。使用“SEGT， ”“乳腺癌”等相关词作为关键词。分析中纳入了比较 SEGT 与乳腺癌患者基线状况的随机对照试验 (RCT)。结果：分析了 10 项研究，共 2,879 名受试者。在生存（风险比 [HR] 0.82，95% 置信区间 [CI] 0.72–0.94；p = 0.004）、短期 QoL（平均差异 [MD] 8.02，95% CI 4.85–11.20；磷#x3c; 0.00001)，长期 QoL（MD 11.30，95% CI 6.75–15.84；p #x3c；0.00001），情绪状态概况评分 (POMS) 评分（MD –0.43，95% CI –0.72 至 –0.13；p = 0.005)、焦虑（标准化 MD [SMD] –0.30，95% CI –0.49 至 –0.10；p = 0.003）和抑郁（SMD –0.47，95 % CI –0.66 至 –0.29；p #x3c；0.00001）。结论： SEGT 可有效改善乳腺癌患者的 QoL 和心理社会状态，但没有令人信服的证据表明它对生存有影响。
肿瘤资源治疗